AU2002346562A1 - Method for treating ocular hypertension - Google Patents

Method for treating ocular hypertension Download PDF

Info

Publication number
AU2002346562A1
AU2002346562A1 AU2002346562A AU2002346562A AU2002346562A1 AU 2002346562 A1 AU2002346562 A1 AU 2002346562A1 AU 2002346562 A AU2002346562 A AU 2002346562A AU 2002346562 A AU2002346562 A AU 2002346562A AU 2002346562 A1 AU2002346562 A1 AU 2002346562A1
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
alkyloxy
hydroxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002346562A
Other languages
English (en)
Inventor
Xavier Billot
Kathleen M Metters
Miller J Ogidigben
Deborah M Slipetz
Robert N Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck and Co Inc
Original Assignee
Merck Frosst Canada Ltd
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd, Merck and Co Inc filed Critical Merck Frosst Canada Ltd
Publication of AU2002346562A1 publication Critical patent/AU2002346562A1/en
Assigned to MERCK FROSST CANADA LTD., MERCK & CO., INC. reassignment MERCK FROSST CANADA LTD. Request for Assignment Assignors: MERCK & CO., INC., MERCK FROSST CANADA & CO.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2002346562A 2001-12-03 2002-11-27 Method for treating ocular hypertension Abandoned AU2002346562A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33811701P 2001-12-03 2001-12-03
US60/338,117 2001-12-03
US40050402P 2002-08-02 2002-08-02
US60/400,504 2002-08-02
PCT/US2002/038040 WO2003047513A2 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension

Publications (1)

Publication Number Publication Date
AU2002346562A1 true AU2002346562A1 (en) 2003-06-17

Family

ID=26991044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346562A Abandoned AU2002346562A1 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension

Country Status (5)

Country Link
EP (1) EP1461026A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005514378A (cg-RX-API-DMAC10.html)
AU (1) AU2002346562A1 (cg-RX-API-DMAC10.html)
CA (1) CA2466757A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003047513A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
AU2002346562A1 (en) * 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. 8−アザプロスタグランジン誘導体およびその医薬用途
US7235586B2 (en) 2003-09-09 2007-06-26 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
CA2569464C (en) 2004-06-04 2012-10-23 Allergan, Inc. 5-thio-piperdinyl prostaglandin e analogs
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
EP2875022B1 (en) * 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
WO2014144500A2 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346562A1 (en) * 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
WO2003047513A2 (en) 2003-06-12
JP2005514378A (ja) 2005-05-19
WO2003047513A3 (en) 2004-07-15
EP1461026A2 (en) 2004-09-29
CA2466757A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
WO2003047513A2 (en) Method for treating ocular hypertension
JP4866992B2 (ja) Ep4受容体作動薬としてのプロスタグランジン類縁体
US20090258918A1 (en) EP4 receptor agonist, compositions and methods thereof
JP2006504679A (ja) 緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体
EP1503984A1 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2002346561B2 (en) EP4 receptor agonist, compositions and methods thereof
JP2005534653A (ja) 眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
US20060167081A1 (en) Ep4 receptor agonists
US20040254230A1 (en) Method for treating ocular hypertension
US20090105234A1 (en) EP4 Receptor Agonist, Compositions and Methods Thereof
AU2002259210A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
AU2004245492B2 (en) 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2011202937B2 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MERCK & CO., INC.; MERCK FROSST CANADA LTD.

Free format text: FORMER APPLICANT(S): MERCK & CO., INC.; MERCK FROSST CANADA & CO.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted